Page 29 - ஜொல்லா நிறுவனம் க்கு நோயெதிர்ப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection. The spike protein is the main surface structure the virus uses to infect host cells and a primary target of neutralizing antibodies following SARS-CoV-2 vaccination or natural infection. The receptor-binding domain (RBD) of this spike mediates the initial stage of infection when it binds to the host cell receptor angiotensin-converting enzyme 2 (ACE2).  

United statesDaniela weiskopfSally robertsonJolla institute for immunologyஒன்றுபட்டது மாநிலங்களில்சாலி ராபர்ட்சன்ஜொல்லா நிறுவனம் க்கு நோயெதிர்ப்பு